The KRAS mutation status is clearly predictive when colorectal cancer patients undergo an anti-EGFR-targeted therapy such as cetumximab.10 Since 5-FU and leucovorin obviously do not specifically target the EGFR-signaling pathway, the KRAS mutation status is not a prognostic factor for RFS in our analysis. The gene discussed is EGFR; the disease is colorectal cancer.